^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KD-496
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
KAEDI
Drug class:
CLDN18.2-targeted CAR-T immunotherapy, NKG2D-targeted CAR-T immunotherapy
Related drugs:
Phase 1
jianming xu
Recruiting
Last update posted :
02/07/2023
Initiation :
10/13/2022
Primary completion :
06/01/2024
Completion :
06/01/2026
CLDN18
|
KD-496
Share
